Skip to main content

Table 1 Clinical characteristics of obese hypertensive and normotensive patients

From: Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study

Compared groups and clinical data

Group A

Group B

Statistical significance p

 

n = 54

n = 11

 

n (%)

(%)

Males/females

20 (37.0%)/34 (63.0%)

5 (45.5%)/6 (54.5)

NS

Age (years)

57.9 ± 11.0

46.1 ± 10.8

p = 0.001

Ischemic heart disease

18 (33.3%)

2 (18.2%)

NS

Myocardial infarct

7 (13.0%)

1 (9.1%)

NS

Cardiac failure

22 (40.7%)

3 (27.3%)

NS

IFG/IGT

34 (63.0%)

4 (36.4%)

NS

CKD

14 (25.9%)

1 (9.1%)

NS

Stroke

3 (5.6%)

0

NS

Cerebral arteries failure

3 (5.6%)

0

NS

Hyperuricemia

24 (44.4%)

2 (18.2%)

NS

Dyslipidaemia

52 (96.3%)

9 (81.8%)

NS

Tobacco smoking

5 (9.3%)

0

NS

ACEI

44 (81.5%)

1 (9.1%)

p < 0.0001

ARB

17 (31.5%)

0

p = 0.05

Diuretics

35 (64.8%)

1 (9.1%)

p < 0.01

CCA

19 (35.2%)

0

p < 0.05

BB

23 (40.7%)

2 (18.2%)

NS

Spironolactone

17 (31.5%)

1 (9.1%)

NS

ARA

7 (13.0%)

0

NS

ASA

15 (27.8%)

1 (9.1%)

NS

Hypolipemic treatment a

31 (57.4%)

4 (36.4%)

NS

  1. IFG – impaired fasting glucose. IGT – impaired glucose tolerance. CKD – chronic kidney disease. COPD – chronic pulmonary obstructive disease. ACEI – angiotensin-converting enzyme inhibitor. ARB – angiotensin II receptor antagonist. CCA – calcium channel antagonist. BB – β-adrenergic receptor blocker. ARA – α1-adrenergic receptor antagonist. ASA – acetylsalicylic acid. NS – not significant. a – statins and/or fibrates.